Catalyst Financial Partners LLC Buys 101 Shares of Zoetis Inc. (NYSE:ZTS)

Catalyst Financial Partners LLC grew its stake in Zoetis Inc. (NYSE:ZTS) by 5.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,047 shares of the company’s stock after acquiring an additional 101 shares during the quarter. Catalyst Financial Partners LLC’s holdings in Zoetis were worth $404,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Vaughan Nelson Investment Management L.P. acquired a new stake in Zoetis during the 3rd quarter worth $176,219,000. Alphinity Investment Management Pty Ltd raised its position in shares of Zoetis by 214.7% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 824,148 shares of the company’s stock worth $162,662,000 after purchasing an additional 562,259 shares during the period. International Assets Investment Management LLC lifted its holdings in shares of Zoetis by 27,671.0% during the 4th quarter. International Assets Investment Management LLC now owns 479,328 shares of the company’s stock valued at $94,605,000 after purchasing an additional 477,602 shares in the last quarter. Envestnet Asset Management Inc. grew its position in shares of Zoetis by 34.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 1,562,044 shares of the company’s stock valued at $271,764,000 after purchasing an additional 403,164 shares during the period. Finally, Natixis Advisors L.P. raised its holdings in Zoetis by 53.9% during the 3rd quarter. Natixis Advisors L.P. now owns 941,219 shares of the company’s stock worth $163,753,000 after buying an additional 329,543 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on ZTS. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. The Goldman Sachs Group reduced their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday. Barclays dropped their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Stifel Nicolaus reduced their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Finally, StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus price target of $211.75.

Zoetis Stock Down 2.1 %

ZTS traded down $3.53 on Wednesday, hitting $164.92. 4,669,191 shares of the company were exchanged, compared to its average volume of 3,195,939. The stock’s fifty day moving average is $167.64 and its 200-day moving average is $178.93. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The company has a market cap of $75.25 billion, a PE ratio of 31.78, a PEG ratio of 2.57 and a beta of 0.86.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period in the previous year, the business earned $1.31 EPS. Zoetis’s revenue for the quarter was up 9.5% compared to the same quarter last year. Equities research analysts predict that Zoetis Inc. will post 5.77 EPS for the current fiscal year.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 2,209 shares of company stock worth $371,293 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.